Appetite-Suppressing Hormone GDF15 May Also Protect the Liver, Researchers Claim

Appetite-Suppressing Hormone GDF15 May Also Protect the Liver, Researchers Claim

Scientists just found that the hormone your body uses to kill your appetite might also be quietly guarding your liver, even if you never lose a single pound.

That hormone is called GDF15, and until recently it was mostly known for one job: appetite suppression. It works by acting on a specific circuit in your brain that essentially signals "stop eating," which is exactly why researchers nicknamed it the weight-loss hormone.

But hormones rarely stick to one job description. The same GDF15 pathway also appears to be involved in the severe nausea and vomiting some women experience during pregnancy, a completely different symptom running through the same biological wiring. One hormone, two very different jobs. And now it looks like there might be a third.

Now there's a third: this same pathway also seems to protect the liver, independent of whatever's happening with appetite or body weight. The hormone that makes you eat less might be quietly running liver-protection duty on the side, whether the scale moves or not.

That matters, because fatty liver disease isn't rare. It's extremely common worldwide, and its more serious, inflammatory form, MASH, shows up especially often in people with obesity or type 2 diabetes.

So the hormone your body already makes to tell you to put the fork down might also be running quiet maintenance somewhere else entirely. Same molecule, at least two very different jobs, and only one of them has anything to do with your appetite.

Sources

  • Endocrine Reviews. "GDF15: A Hormone Conveying Somatic Distress to the Brain." 2020.
  • PNAS. "GFRAL-expressing neurons suppress food intake via aversive pathways." 2021.
  • Fejzo et al. "GDF15 linked to maternal risk of nausea and vomiting during pregnancy." 2023.
  • PMC. "GDF15 Targeting for Treatment of Hyperemesis Gravidarum."
  • PMC. "Estimated Burden of Metabolic Dysfunction–Associated Steatotic Liver Disease in US Adults, 2020 to 2050."
  • The Lancet Regional Health – Europe. "A call for doubling the diagnostic rate of at-risk metabolic dysfunction-associated steatohepatitis." 2025.
#Science#DidYouKnow#1MinSpentWell

Comments

No comments yet — be the first.